WaveMan
WaveMan · Company
SILO · Silo Pharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SILO Silo Pharma (SILO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001514183
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter

Silo Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Silo Pharma, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Weisblum Eric
Chief Executive Officer
BUY
2025-12-16 SECtraded 2025-12-15
2,500
$1.1K
-80.7%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 buys), the last on Nov 21, 2025.
  • -1.8% median (-0.9% mean) 90-day return after 30 previous buys.
  • The trade is 1.2% of the 216,932 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Weisblum Eric bought about $1.1K of SILO on Dec 15, 2025; 2 funds added in the latest 13F quarter.
Weisblum Eric
Chief Executive Officer
BUY
2025-12-16 SECtraded 2025-12-15
2,500
$1.0K
-80.7%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 buys), the last on Nov 21, 2025.
  • -1.8% median (-0.9% mean) 90-day return after 30 previous buys.
  • The trade is 1.2% of the 214,432 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Weisblum Eric bought about $1.0K of SILO on Dec 15, 2025; 2 funds added in the latest 13F quarter.
Weisblum Eric
Chief Executive Officer
BUY
2025-11-21 SEC
1,000
$370
-81.8%
Context
  • 37 earlier Form 4 trades (code P or S) here by this insider (37 buys), the last on Nov 20, 2025.
  • -1.8% median (-0.3% mean) 90-day return after 30 previous buys.
  • The trade is 0.5% of the 211,932 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Weisblum Eric bought about $370 of SILO on Nov 21, 2025; 2 funds added in the latest 13F quarter.
Weisblum Eric
Chief Executive Officer
BUY
2025-11-21 SECtraded 2025-11-20
1,000
$370
-81.8%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 buys), the last on Nov 19, 2025.
  • -1.8% median (-0.8% mean) 90-day return after 30 previous buys.
  • The trade is 0.5% of the 210,932 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Weisblum Eric bought about $370 of SILO on Nov 20, 2025; 2 funds added in the latest 13F quarter.
Weisblum Eric
Chief Executive Officer
BUY
2025-11-20 SECtraded 2025-11-19
4,500
$1.8K
-80.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 buys), the last on Nov 18, 2025.
  • -1.8% median (-1.0% mean) 90-day return after 30 previous buys.
  • The trade is 2.1% of the 209,932 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Weisblum Eric bought about $1.8K of SILO on Nov 19, 2025; 2 funds added in the latest 13F quarter.
41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 36 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
the lowest in Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.4% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SILO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-86.1%12M
-86%-51%-16%+19%2025-102025-122026-022026-042026-062026-082026-10 2025-11-18 · Weisblum Eric bought $3.0K2025-11-19 · Weisblum Eric bought $1.8K2025-12-15 · Weisblum Eric bought $1.1K2025-12-15 · Weisblum Eric bought $1.0K2025-11-20 · Weisblum Eric bought $3702025-11-21 · Weisblum Eric bought $370
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SILO: institutional holders (13F)

13F holdings, latest reported quarter
AdvisorShares Investments LLC
75,582 sh
$469.4K
CITADEL ADVISORS LLC
16,800 sh
$104.3K
VANGUARD CAPITAL MANAGEMENT LLC
11,956 sh
$74.2K
VANGUARD FIDUCIARY TRUST CO
874 sh
$5.4K
Tower Research Capital LLC (TRC)
181 sh
$1.1K

Congress trades in SILO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SILO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SILO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$469.4K position · as of 2026-06-30
1.1%
Fidelity Extended Market Index Fund
$61.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$74.2K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$3.6K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$1.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Eric Weisblum
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$521.8K
$498.5K
$101.5K
-98%
n/a
2024
$630.1K
$630.1K
$88.6K
-94%
n/a
2023
$569.0K
$569.0K
$62.7K
-93%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SILO financials

Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$54.1K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-91.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-71.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-85.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$72.1K$72.1K$72.1K$72.1K
Gross profit$27.8K$66.3K$66.3K$66.3K
Operating income-$4.3M-$4.7M-$3.9M-$3.6M
Net income-$4.2M-$4.4M-$3.7M-$3.9M
EPS (diluted)-0.50-1.19-1.20n/a
Operating cash flow-$4.7M-$3.8M-$3.2M-$3.5M
Cash$4.7M$3.9M$3.5M$11.4M
SEC XBRL, fiscal years, as known on 2026-10-28

SILO Stock Sonar score 4/7 axes

Find similar shapesCompare

SILO ranks highest on growth (44th percentile) and risk and compliance (42nd), and lowest on institutional and government (1st), among Pharma & Biotech peers.

Profitability
33
Inputs
  • Return on equity-91.2% · 36 pct, sector of 545
  • Return on assets-71.0% · 34 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-85.1% · 31 pct, sector of 576
Growth
44
Inputs
  • Revenue growth, YoY+0.0% · 44 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
0
Inputs
  • Funds adding, latest quarter2 · 0 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
42
Inputs
  • Short interest, % of float+1.4% · 77 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+29.5% · 8 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies